[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR3075200B1 - Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc - Google Patents

Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc Download PDF

Info

Publication number
FR3075200B1
FR3075200B1 FR1762217A FR1762217A FR3075200B1 FR 3075200 B1 FR3075200 B1 FR 3075200B1 FR 1762217 A FR1762217 A FR 1762217A FR 1762217 A FR1762217 A FR 1762217A FR 3075200 B1 FR3075200 B1 FR 3075200B1
Authority
FR
France
Prior art keywords
fragment
increased affinity
fcrn
variants
receiver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1762217A
Other languages
English (en)
Other versions
FR3075200A1 (fr
Inventor
Harry Meade
Celine Monnet
Philippe Mondon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1762217A priority Critical patent/FR3075200B1/fr
Application filed by LFB SA filed Critical LFB SA
Priority to JP2020532813A priority patent/JP2021508444A/ja
Priority to KR1020207016305A priority patent/KR20200098512A/ko
Priority to MX2020006013A priority patent/MX2020006013A/es
Priority to RU2020119543A priority patent/RU2820162C2/ru
Priority to CN202410817266.9A priority patent/CN118812703A/zh
Priority to BR112020012016-2A priority patent/BR112020012016A2/pt
Priority to EP18829783.2A priority patent/EP3724221A1/fr
Priority to US16/772,244 priority patent/US20210214434A1/en
Priority to CN201880080414.6A priority patent/CN111601821B/zh
Priority to PCT/EP2018/084970 priority patent/WO2019115773A1/fr
Priority to CA3084602A priority patent/CA3084602A1/fr
Priority to AU2018382593A priority patent/AU2018382593A1/en
Publication of FR3075200A1 publication Critical patent/FR3075200A1/fr
Application granted granted Critical
Publication of FR3075200B1 publication Critical patent/FR3075200B1/fr
Priority to JP2023113380A priority patent/JP2023134604A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR1762217A 2017-12-15 2017-12-15 Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc Active FR3075200B1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FR1762217A FR3075200B1 (fr) 2017-12-15 2017-12-15 Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
PCT/EP2018/084970 WO2019115773A1 (fr) 2017-12-15 2018-12-14 Variants avec fragment fc ayant une affinité augmentée pour fcrn et une affinité augmentée pour au moins un récepteur du fragment fc
MX2020006013A MX2020006013A (es) 2017-12-15 2018-12-14 Variantes con fragmento de fc que tienen una mayor afinidad por el receptor de fc neonatal (fcrn) y una mayor afinidad por al menos un receptor del fragmento de fc.
RU2020119543A RU2820162C2 (ru) 2017-12-15 2018-12-14 Варианты с fc-фрагментом, обладающие повышенной аффинностью к fcrn и повышенной аффинностью по меньшей мере к одному рецептору fc-фрагмента
CN202410817266.9A CN118812703A (zh) 2017-12-15 2018-12-14 具有对FcRn的亲和力提高以及对至少一个Fc片段受体的亲和力提高的Fc片段的变体
BR112020012016-2A BR112020012016A2 (pt) 2017-12-15 2018-12-14 variantes com fragmento fc com uma afinidade aumentada para fcrn e uma afinidade aumentada para pelo menos um receptor do fragmento fc
EP18829783.2A EP3724221A1 (fr) 2017-12-15 2018-12-14 Variants avec fragment fc ayant une affinité augmentée pour fcrn et une affinité augmentée pour au moins un récepteur du fragment fc
US16/772,244 US20210214434A1 (en) 2017-12-15 2018-12-14 Variants with fc fragment having an increased affinity for fcrn and an increased affinity for at least one receptor of the fc fragment
JP2020532813A JP2021508444A (ja) 2017-12-15 2018-12-14 ＦｃＲｎに対する増大した親和性および少なくとも１つのＦｃフラグメント受容体に対する増大した親和性を有するＦｃフラグメントを伴う変異体
KR1020207016305A KR20200098512A (ko) 2017-12-15 2018-12-14 FcRn에 대한 증가된 친화성 및 적어도 하나의 Fc 단편 수용체에 대한 증가된 친화성을 가진 Fc 단편을 가진 변이체
CA3084602A CA3084602A1 (fr) 2017-12-15 2018-12-14 Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
AU2018382593A AU2018382593A1 (en) 2017-12-15 2018-12-14 Variants with Fc fragment having an increased affinity for FcRn and an increased affinity for at least one receptor of the Fc fragment
CN201880080414.6A CN111601821B (zh) 2017-12-15 2018-12-14 具有对FcRn的亲和力提高以及对至少一个Fc片段受体的亲和力提高的Fc片段的变体
JP2023113380A JP2023134604A (ja) 2017-12-15 2023-07-11 ＦｃＲｎに対する増大した親和性および少なくとも１つのＦｃフラグメント受容体に対する増大した親和性を有するＦｃフラグメントを伴う変異体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1762217 2017-12-15
FR1762217A FR3075200B1 (fr) 2017-12-15 2017-12-15 Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc

Publications (2)

Publication Number Publication Date
FR3075200A1 FR3075200A1 (fr) 2019-06-21
FR3075200B1 true FR3075200B1 (fr) 2022-12-23

Family

ID=62816603

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1762217A Active FR3075200B1 (fr) 2017-12-15 2017-12-15 Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc

Country Status (11)

Country Link
US (1) US20210214434A1 (fr)
EP (1) EP3724221A1 (fr)
JP (2) JP2021508444A (fr)
KR (1) KR20200098512A (fr)
CN (2) CN118812703A (fr)
AU (1) AU2018382593A1 (fr)
BR (1) BR112020012016A2 (fr)
CA (1) CA3084602A1 (fr)
FR (1) FR3075200B1 (fr)
MX (1) MX2020006013A (fr)
WO (1) WO2019115773A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3101640B1 (fr) 2019-10-07 2024-04-12 Lab Francais Du Fractionnement Lignée cellulaire de monocytes humains et son utilisation en tant que modèle cellulaire de la phagocytose.
JP2023531141A (ja) * 2020-05-21 2023-07-21 ザイダス・ライフサイエンシーズ・リミテッド Ｆｃバリアント及びその調製
KR102341138B1 (ko) 2020-05-31 2021-12-21 주식회사 엑소코바이오 엑소좀의 막단백질 변이체를 포함하는 엑소좀 및 이의 제조방법
KR20220101559A (ko) 2021-01-11 2022-07-19 주식회사 엑소코바이오 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법
KR20220106696A (ko) 2021-01-21 2022-07-29 주식회사 엑소코바이오 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도
WO2023191766A1 (fr) * 2022-03-28 2023-10-05 Intervexion Therapeutics, Llc Anticorps ayant une affinité de fcrn modifiée

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE141646T1 (de) 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1697415A1 (fr) * 2003-11-12 2006-09-06 Biogen Idec MA Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
EP2233500A1 (fr) * 2009-03-20 2010-09-29 LFB Biotechnologies Variantes Fc optimisées
FR2957598B1 (fr) * 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
US20170129966A1 (en) * 2014-06-02 2017-05-11 Laboratoire Français Du Fractionnement Et Des Biotechnologies Production of fc fragments
FR3024453B1 (fr) * 2014-08-01 2018-06-29 Lab Francais Du Fractionnement Procede de production de variants ayant un fc presentant une sialylation amelioree
FR3035879A1 (fr) * 2015-05-07 2016-11-11 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
FR3051794A1 (fr) * 2016-05-31 2017-12-01 Lab Francais Du Fractionnement Anticorps pour le traitement de cancers
FR3053688A1 (fr) * 2016-07-06 2018-01-12 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Mutants fc a activite fonctionnelle amelioree

Also Published As

Publication number Publication date
CN111601821A (zh) 2020-08-28
FR3075200A1 (fr) 2019-06-21
KR20200098512A (ko) 2020-08-20
EP3724221A1 (fr) 2020-10-21
US20210214434A1 (en) 2021-07-15
CN111601821B (zh) 2024-06-14
MX2020006013A (es) 2020-08-17
BR112020012016A2 (pt) 2020-11-24
RU2020119543A (ru) 2021-12-13
WO2019115773A1 (fr) 2019-06-20
AU2018382593A1 (en) 2020-06-25
CA3084602A1 (fr) 2019-06-20
JP2023134604A (ja) 2023-09-27
JP2021508444A (ja) 2021-03-11
CN118812703A (zh) 2024-10-22

Similar Documents

Publication Publication Date Title
FR3075200B1 (fr) Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
MA46534A (fr) Protéines de fusion fc hétérodimères il15/il15r
DK3389699T3 (da) Kimæriske og humaniserede anti-humane CTLA4-monoklonale antistoffer og anvendelser deraf
CL2016000033S1 (es) Botella.
IL254403A0 (en) Methods for lowering the amount of fc-containing substances in the serum by using fcrn antibodies
DK3795177T3 (da) Claudin-18.2-specifikke immunoreceptorer og t-celleepitoper
CL2019001188S1 (es) Botella.
DK3262163T3 (da) Fusariumtoxin spaltende polypeptidvarianter, additiver indeholdende samme og anvendelse af samme samt fremgangsmåde til spaltning af fusariumtoxiner
DK3286223T5 (da) Kappa myeloma antigen chimær antigen receptorer og anvendelser deraf
GEP20217290B (en) Masp-2 antibodies for inhibiting fibrosis
IL266860A (en) A polypeptide bearing a chemical group and containing an antigen-binding complex
DK3356408T3 (da) Humaniserede anti-humane CD19-antistoffer og fremgangsmåder til anvendelse
FR3021748B1 (fr) Procede pour l'evaluation d'au moins une caracteristique petroliere d'un echantillon de roche
IL272561A (en) Antibodies with modified FC variants to increase half-life in the blood
DK3445785T3 (da) Humaniserede anti-clever-1-antistoffer og anvendelse deraf
MA52099A (fr) Récolte sélective automatisée avec systèmes et procédés associés
IL283491A (en) Device for flow tests
IL248320A0 (en) Recombinant monoclonal vnar antibodies that neutralize the vascular endothelial growth factorvegf
FR3049924B1 (fr) Structure offshore comportant au moins un chaumard
CL2018003839S1 (es) Botella.
FR3029945B1 (fr) Procede de mise en place d'une installation sous-marine comportant au moins un troncon de conduite, et installation associee
CL2019000896S1 (es) Botella.
DK3545132T3 (da) Indretning, svejsemanchet og fremgangsmåde til stødsvejsning af skinnebrud
CL2020000585S1 (es) Botella.
DE102019108259A8 (de) Sattelfahrzeug

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20190621

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

CA Change of address

Effective date: 20221108

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7